Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ningxia Xinhua Chemical Co. Ltd. is currently navigating the prosecution process with 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's active matters involve 1 distinct examiner and 1 distinct art unit. This structure reflects a singular focus in their current patenting efforts, where all pending legal resources are directed toward a single application. The lack of broader distribution across different art units suggests that the company is pursuing a very specific technological path at this time.
The busiest examiner for the portfolio is BONAPARTE, AMY C, who holds 1 busiest examiner pending office action. As this examiner is the sole point of contact for the company's pending actions, the outcome of the current prosecution cycle is tied to this specific relationship. Practitioners should focus on the history of BONAPARTE, AMY C within the Biotechnology & Pharmaceuticals sector to inform their strategy. Understanding the specific preferences and common rejections issued by this examiner will be vital for advancing the Ningxia Xinhua Chemical Co. Ltd. application toward allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BONAPARTE, AMY C | 1 | 79.1% | +23.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18288957 | SYNTHETIC METHOD AND CATALYST OF 3-(3-OXO-2-PENTYL)CYCLOPENTYL DIMETHYL MALONATE | BONAPARTE, AMY C | — |
| Art Unit | Apps |
|---|---|
| 1692 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18288957 | SYNTHETIC METHOD AND CATALYST OF 3-(3-OXO-2-PENTYL)CYCLOPENTYL DIMETHYL MALONATE | BONAPARTE, AMY C | 1692 | §103 | Non-Final OA | — | Pending | Oct 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNingxia Xinhua Chemical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amy C Bonaparte has the most, with 1 of Ningxia Xinhua Chemical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
